Pathfinder Cell Therapy, Inc.
PFND
$0.00
$0.000.00%
OTC PK
| 09/30/2015 | 06/30/2015 | 03/31/2015 | 12/31/2014 | 09/30/2014 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | 0.00 |
| Cost of Revenue | -- | -- | -- | -- | 13.00K |
| Gross Profit | -- | -- | -- | -- | -13.00K |
| SG&A Expenses | 610.00K | 659.00K | 743.00K | 857.00K | 961.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 775.00K | 779.00K | 900.00K | 1.12M | 1.31M |
| Operating Income | -775.00K | -779.00K | -900.00K | -1.12M | -1.31M |
| Income Before Tax | -1.08M | -1.08M | -1.19M | -1.39M | -1.56M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.08 | -1.08 | -1.19 | -1.39 | -1.56 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.08M | -1.08M | -1.19M | -1.39M | -1.56M |
| EBIT | -775.00K | -779.00K | -900.00K | -1.12M | -1.31M |
| EBITDA | -772.00K | -776.00K | -897.00K | -1.12M | -1.31M |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 2.67B | 2.67B | 2.67B | 2.67B | 2.67B |
| Average Diluted Shares Outstanding | 2.67B | 2.67B | 2.67B | 2.67B | 2.67B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |